# Effects of Early Correction of Anemia in Patients With Chronic Renal Insufficiency

> **NCT00312871** · PHASE4 · TERMINATED · sponsor: **Janssen Cilag S.A.S.** · enrollment: 217 (actual)

## Conditions studied

- Anemia
- Renal Failure, Chronic Renal Failure

## Interventions

- **DRUG:** Epoetin alfa

## Key facts

- **NCT ID:** NCT00312871
- **Lead sponsor:** Janssen Cilag S.A.S.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2001-02
- **Primary completion:** —
- **Final completion:** 2003-06
- **Target enrollment:** 217 (ACTUAL)
- **Why stopped:** Study was stopped due to restrictions in labeling for the subcutaneous route of administration of EPREX.
- **Last updated:** 2011-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00312871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00312871, "Effects of Early Correction of Anemia in Patients With Chronic Renal Insufficiency". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00312871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*